#GynCSM Transcript
Healthcare social media transcript of the #GynCSM hashtag.
– ().
See #GynCSM Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | GYN Cancer | #GYNCSM @gyncsm Welcome to #gyncsm - a passionate community for gynecologic cancer survivors, caregivers, advocates and health care providers. |
 | Dee Sparacio @womenofteal RT @gyncsm: Welcome to #gyncsm - a passionate community for gynecologic cancer survivors, caregivers, advocates and health care providers. |
| GYN Cancer | #GYNCSM @gyncsm Our co-moderators are @womenofteal @btrfly12 Our health care moderators are @ShannonWestin @temkins @journeycancer and our mental health moderator @DrBeckerSchutte We start out with brief intro’s - Please take a moment to introduce yourself. :) #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Our co-moderators are @womenofteal @btrfly12 Our health care moderators are @ShannonWestin @temkins @journeycancer and our mental health moderator @DrBeckerSchutte We start out with brief intro’s - Please take a moment to introduce yourself. :) #gyncsm |
 | Sarah Temkin @temkins RT @gyncsm: Our co-moderators are @womenofteal @btrfly12 Our health care moderators are @ShannonWestin @temkins @journeycancer and our mental health moderator @DrBeckerSchutte We start out with brief intro’s - Please take a moment to introduce yourself. :) #gyncsm |
 | Christina Lizaso @btrfly12 Hi #gyncsm :) I'm Christina Lizaso – passionate re: community engagement and cancer care - and I’ll be moderating as @gyncsm today. |
| Dee Sparacio @womenofteal Dee here! Dx with #ovca Stage3B 2005, recurrence 2008, Ovarian Cancer research advocate, blogger & co-moderator #gyncsm |
 | Tanya Temkin @tanyaltee Hi. Tanya here, stage 4 HGSOC survivor after a long absence from Twitter. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm If you prefer to “listen only” during the chat, we'd love for you to tweet "#gyncsm" when you join - just to let us know you are here. Please continue intro's and welcomes - we'll start in w/ the "ground rules" :) and chat tips! |
 | Michele E. Collins @Michele_w_1_L Michele from Jersey. 6 Year Survivor Stage 2B High Grade Serous Ovarian Cancer #gyncsm |
| Dee Sparacio @womenofteal Coming off of 5 exciting days of #ASCO21 looking forward to discussing the latest research. #gyncsm |
| Dee Sparacio @womenofteal @tanyaltee Hi Tanya, Glad to see you tonight! #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: If you prefer to “listen only” during the chat, we'd love for you to tweet "#gyncsm" when you join - just to let us know you are here. Please continue intro's and welcomes - we'll start in w/ the "ground rules" :) and chat tips! |
| GYN Cancer | #GYNCSM @gyncsm The #gyncsm chat promotes community in a public forum. Learn more about risks/benefits: https://t.co/TipZUv1jQy |
 | Christine (Cissy) White @healWRITEnow #gyncsm cissy here. Diagnosed stage 3b in 2019 & recurred in 2020. Currently on chemo & hoping for cancer unicorn status til #oncology has more effective prevention, screening, & treatment. |
 | Chezilme 🏳️🌈🇨🇦🇨🇵 @chezilme RT @btrfly12: Join/Share: Join/Share: #gyncsm chat on Wed, June 9th, 8pmET https://t.co/qSWYS2Wod4 https://t.co/m0CTPaXvvi |
| GYN Cancer | #GYNCSM @gyncsm Are you new to tweet chats? Follow hashtag #gyncsm and include it in every tweet during the next hour to engage with others about this topic. |
| Dee Sparacio @womenofteal @Michele_w_1_L Hi Michele So glad to see you here tonight - The thunderstorms have been pretty loud today haven't they. #gyncsm |
| Dee Sparacio @womenofteal @healWRITEnow Hi Cissy Good to see you. #gyncsm |
 | Tobey @BRCAinfo Hi everyone. Sorry I’m late~ fur baby took her time tonight! #gyncsm |
| Dee Sparacio @womenofteal #gyncsm tagged resources and referrals are not a substitute for speaking with your doctor who understands your needs and history. #gyncsm |
| Dee Sparacio @womenofteal @BRCAinfo Hi Tobey - I just took my dogs out too. In between the raindrops #gyncsm |
| Dee Sparacio @womenofteal Remember - Twitter is an open social network and posts are public. Use a Direct Message to exchange email addresses/personal information.#gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Wonderful group gathering for #gyncsm We also welcome all those “listening in”. You can tweet #gyncsm so we know you are here. You can also tweet, DM or email us with questions/comments after the chat is over. https://t.co/XYaP3OTgsG |
| Dee Sparacio @womenofteal RT @gyncsm: Wonderful group gathering for #gyncsm We also welcome all those “listening in”. You can tweet #gyncsm so we know you are here. You can also tweet, DM or email us with questions/comments after the chat is over. https://t.co/XYaP3OTgsG |
| Dee Sparacio @womenofteal Thank you to all who have tweeted valuable information to our community during the #ASCO21 meeting using the #gyncsm hashtag. And we appreciate those who helped promote tonight's chat. |
| GYN Cancer | #GYNCSM @gyncsm Tonight on #gyncsm we’ll be discussing Gyn Cancer Research News - mainly from the SGO and ASCO meetings. SGO is the Society for Gynecologic Oncology and ASCO is the American Society of Clinical Oncology. |
 | IamCervivor @IamCervivor @gyncsm We’re here! #gyncsm |
| Tobey @BRCAinfo @womenofteal I don’t miss the north ~ luvin Florida #gyncsm |
 | Shannon Westin, MD, MPH, FASCO @ShannonWestin Hey there #gyncsm- I am a Gyn onc from @MDAndersonNews Excited that I finally made the time change! |
| GYN Cancer | #GYNCSM @gyncsm We’ll use a topic format with T1; T2 etc. Please include the corresponding T# at the front of your comment or answer. We will wrap up with a chance to share TIL: thoughts standing for “Today I Learned”. #gyncsm |
| IamCervivor @IamCervivor RT @gyncsm: Tonight on #gyncsm we’ll be discussing Gyn Cancer Research News - mainly from the SGO and ASCO meetings. SGO is the Society for Gynecologic Oncology and ASCO is the American Society of Clinical Oncology. |
| Christine (Cissy) White @healWRITEnow @womenofteal You too, @womenofteal #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm You can find the 7 questions we’ll cover on today’s chat on our #gyncsm blog page: https://t.co/RJhttN1BMz Here comes Topic 1 (T1:)... |
| Dee Sparacio @womenofteal RT @gyncsm: We’ll use a topic format with T1; T2 etc. Please include the corresponding T# at the front of your comment or answer. We will wrap up with a chance to share TIL: thoughts standing for “Today I Learned”. #gyncsm |
 | Uterine Cancer Awareness Network @ucan2020 RT @btrfly12: Thanks again for joining last month's #gyncsm chat: @IamCervivor @NitaKarnikLee @BRCAinfo @Michele_w_1_L @healWRITEnow @patsyhinson @GlobalRadOnc @MIShouldTalk @ucan2020 Here's the information about tonight's chat: https://t.co/8mkKF5945l |
| Dee Sparacio @womenofteal RT @gyncsm: You can find the 7 questions we’ll cover on today’s chat on our #gyncsm blog page: You can find the 7 questions we’ll cover on today’s chat on our #gyncsm blog page: https://t.co/RJhttN1BMz Here comes Topic 1 (T1:)... |
| Christine (Cissy) White @healWRITEnow @womenofteal Can’t wait for your take on highlights & hope. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm T1: What #SGOMtg presentations did you personally find of most interest? Anything practice-changing to note? [ SGO Abstracts link https://t.co/ifLCrXEJKt ] #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: T1: T1: What #SGOMtg presentations did you personally find of most interest? Anything practice-changing to note? [ SGO Abstracts link https://t.co/ifLCrXEJKt ] #gyncsm |
| Dee Sparacio @womenofteal T1 The best part for me was a discussion (debate might be a better word ) on secondary cytoreductive surgery between Dr Gardner and Dr Coleman . #SGOmtg #gyncsm https://t.co/ISS2zbs59S |
 | Nita Lee @NitaKarnikLee @gyncsm Hi everyone #gyncsm gyn onc in Chicago @UCCancerCenter @uchicago_obgyn . Great topic I’m very interested to hear what advocates also felt were the most interesting and important topics |
| Dee Sparacio @womenofteal @NitaKarnikLee @gyncsm @UCCancerCenter @uchicago_obgyn So glad you could join us! #gyncsm |
| Christina Lizaso @btrfly12 T1: Glad to see continued learning on PARPs. Immunotherapy seems to still need lots of figuring out. Sobering info on female experiences in GynOnc - being a majority female specialty but still wage gap, bullying, etc. #gyncsm |
 | Amy Byer Shainman @BRCAresponder Hi #gyncsm lurking tonight. |
| Christina Lizaso @btrfly12 T1: Also glad to see more studies on financial toxicity. #gyncsm |
| Amy Byer Shainman @BRCAresponder RT @gyncsm: Tonight on #gyncsm we’ll be discussing Gyn Cancer Research News - mainly from the SGO and ASCO meetings. SGO is the Society for Gynecologic Oncology and ASCO is the American Society of Clinical Oncology. |
| GYN Cancer | #GYNCSM @gyncsm T2: There was a session at #SGOmtg entitled "Time to Return to the Drawing Board: Learning From Negative Trials." What are "negative" trials and what are some key take-aways? #gyncsm |
| Tobey @BRCAinfo @btrfly12 I’m very interested in #Immunotherapy I wish the researchers would hurry up! #gyncsm |
 | Gary L. Thompson @garyleethompson @btrfly12 Quick hello from Austin, TX to #gyncsm 💕💕 |
| Dee Sparacio @womenofteal RT @gyncsm: T2: There was a session at #SGOmtg entitled "Time to Return to the Drawing Board: T2: There was a session at #SGOmtg entitled "Time to Return to the Drawing Board: Learning From Negative Trials." What are "negative" trials and what are some key take-aways? #gyncsm |
| Dee Sparacio @womenofteal @garyleethompson @btrfly12 Hi Gary - Glad you could stop by. #gyncsm |
| Tanya Temkin @tanyaltee I’m mostly going to be lurking too, since I’ve been on LOA from most social media/advocacy while dealing with recurrence. #gyncsm |
| Christina Lizaso @btrfly12 T1: This SGO study was mentioned by my GYN - that maybe my IUD can counter-effect incr endo risk from tamoxifen: Hormonal IUD Shows Promise as an Effective Treatment for Early Endometrial Cancer or Precancer https://t.co/cK0TXP8QTT #gyncsm |
| Christina Lizaso @btrfly12 RT @gyncsm: T2: There was a session at #SGOmtg entitled "Time to Return to the Drawing Board: T2: There was a session at #SGOmtg entitled "Time to Return to the Drawing Board: Learning From Negative Trials." What are "negative" trials and what are some key take-aways? #gyncsm |
| Dee Sparacio @womenofteal T2 #SGOMtg Phase II Durvalumab (anti-PDL1)& Tremelimumab (anti-CTLA4) Administered in Combo versus Sequentially for the Treatment of Recurrent HGSOC No diff between arms in PFS Clear cell histology should be examined #gyncsm |
| Christina Lizaso @btrfly12 @tanyaltee Glad you are here and that you took the time you needed for you :) #gyncsm |
| Dee Sparacio @womenofteal T2 I think hearing about treatments that are tried yet don't give the results the researchers expect are still valuable to hear about. #gyncsm |
| Tanya Temkin @tanyaltee I have a lot of catch-up reading to do. Especially interested in any research on PARP after PARP. #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin @btrfly12 This was eye opening! #gyncsm |
| Nita Lee @NitaKarnikLee #gyncsm T1: @womenofteal is it fair I retweet some of your own posts from #sgomtg this study on vulvar cancer and immunotherapy was important often under studied topic |
| Christina Lizaso @btrfly12 2/2... Another recent study showed general ovarian screening over time not effective. Hard to learn but glad for these studies. #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin Very excited to get the final results for this combination in pts w clear cell #OvarianCancer I am hopeful that some of our translational analyses will help identify who benefits from #Immunotherapy #gyncsm |
| Christina Lizaso @btrfly12 #gyncsm RT @SuzieSiegel "In #sarcoma, the olaratumab trial failed to reach its goals. But it did spur a lot of thinking on trial design." |
 | Suzie Siegel @SuzieSiegel Forgot #gyncsm. Sorry I'm late to the chat. This was the only study I saw related to uterine #sarcoma at SGO |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin We presented some data at #ASCO21 - Novel combinations may be able to overcome resistance to #PARPi. #gyncsm |
| Nita Lee @NitaKarnikLee @btrfly12 #gyncsm very true! Glad to see this emphasized as well |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @NitaKarnikLee: #gyncsm T1: #gyncsm T1: @womenofteal is it fair I retweet some of your own posts from #sgomtg this study on vulvar cancer and immunotherapy was important often under studied topic |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @btrfly12: 2/2... Another recent study showed general ovarian screening over time not effective. Hard to learn but glad for these studies. #gyncsm |
| Dee Sparacio @womenofteal @NitaKarnikLee Sure thing. I'm glad to be RTd and to RT others especially when the meetings move so fast, #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @btrfly12: #gyncsm RT @SuzieSiegel "In #sarcoma, the olaratumab trial failed to reach its goals. But it did spur a lot of thinking on trial design." |
| Dee Sparacio @womenofteal RT @NitaKarnikLee: #gyncsm T1: #gyncsm T1: @womenofteal is it fair I retweet some of your own posts from #sgomtg this study on vulvar cancer and immunotherapy was important often under studied topic |
 | Patsy Hinson @patsyhinson T2 hard to hear about Negative trials. We learn what not to do; however, it’s disheartening for those in treatment. #gyncsm |
| Dee Sparacio @womenofteal RT @ShannonWestin: Very excited to get the final results for this combination in pts w clear cell #OvarianCancer I am hopeful that some of our translational analyses will help identify who benefits from #Immunotherapy #gyncsm |
| Dee Sparacio @womenofteal RT @btrfly12: #gyncsm RT @SuzieSiegel "In #sarcoma, the olaratumab trial failed to reach its goals. But it did spur a lot of thinking on trial design." |
| GYN Cancer | #GYNCSM @gyncsm T3: Which #ASCO21 studies do you think may be of most interest to patients? [ ASCO Abstracts link https://t.co/PlP2JFRsQZ ] #gyncsm |
 | Colletta Orr @CollettaOrr RT @ShannonWestin: Very excited to get the final results for this combination in pts w clear cell #OvarianCancer I am hopeful that some of our translational analyses will help identify who benefits from #Immunotherapy #gyncsm |
 | Don S. Dizon MD (he/him) 🇬🇺 @drdonsdizon @ShannonWestin #gyncsm Nivo/Ipi vs Nivo in extra renal clear cell enrolling @RIHospital @womenandinfants and soon @UIChicagoIL Let's finish and define activity level of i/o in clear cell!! |
| Patsy Hinson @patsyhinson First I have heard about possibility of overcoming parp resistance. Was so encouraged listening to ASCO #gyncsm |
| Christina Lizaso @btrfly12 T1: Here's a link to the #SGOMtg recap of media coverage following their conference. Good place to start and figure out what you might want to dig deeper into. #gyncsm https://t.co/y2SlEgnl9x |
| Dee Sparacio @womenofteal It is true when you hear a treatment talked up to learn it may not be as beneficial as thought. But in some cases the trials will show a subset of patients that do benefit. A more personalized approach. #gyncsm |
| Christina Lizaso @btrfly12 RT @patsyhinson: T2 hard to hear about Negative trials. We learn what not to do; however, it’s disheartening for those in treatment. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: T3: T3: Which #ASCO21 studies do you think may be of most interest to patients? [ ASCO Abstracts link https://t.co/PlP2JFRsQZ ] #gyncsm |
| Dee Sparacio @womenofteal RT @drdonsdizon: @ShannonWestin #gyncsm Nivo/Ipi vs Nivo in extra renal clear cell enrolling @RIHospital @womenandinfants and soon @UIChicagoIL Let's finish and define activity level of i/o in clear cell!! |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin T3- definitely a theme of more is not always better. Longer duration of bevacizumab in upfront maintenance did not improve survival in #OvarianCancer #gyncsm |
| IamCervivor @IamCervivor RT @btrfly12: T1: T1: Here's a link to the #SGOMtg recap of media coverage following their conference. Good place to start and figure out what you might want to dig deeper into. #gyncsm https://t.co/y2SlEgnl9x |
| Christina Lizaso @btrfly12 T3: From #ASCO21 I saw diversity and patient voice being highlighted in what seemed to be genuine ways. Long way to go but nice to see. The study about helping "light up" tumor so it can be removed looked fascinating. #gyncsm |
| Dee Sparacio @womenofteal @patsyhinson I was excited to hear about that too @ShannonWestin Please share a bit about your research. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm T4: What are some of the "hot topics" in gynecologic cancer research currently (PARPs, cytoreductive surgery, immunotherapy, other)? What is still up for debate that patients/survivors/advocates should be aware of? #gyncsm |
| Suzie Siegel @SuzieSiegel @btrfly12 It was great that @ASCO let patient advocates register for free. I never found out ... did @SGO_org charge advocates? #gyncsm |
| Dee Sparacio @womenofteal T1 a great overview @ocrahope of #SGOmtg from advocates @Stigetta and @KathleenMaxian https://t.co/cdQIVm5yRv #gyncsm |
| Dee Sparacio @womenofteal RT @ShannonWestin: T3- definitely a theme of more is not always better. Longer duration of bevacizumab in upfront maintenance did not improve survival in #OvarianCancer #gyncsm |
| Gary L. Thompson @garyleethompson @womenofteal @btrfly12 Going to lurk and listen tonight… blessings to all at #gyncsm 💖 |
| Christina Lizaso @btrfly12 RT @womenofteal: T1 a great overview @ocrahope of #SGOmtg from advocates @Stigetta and @KathleenMaxian https://t.co/cdQIVm5yRv #gyncsm |
| Christina Lizaso @btrfly12 @garyleethompson @womenofteal So good to have you stop by. Blessings to you and yours as well :) #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin We evaluated the wee1 inhibitor adavosertib alone or in combination with olaparib in women w #PARPi resistant #OvarianCancer - we saw activity in both arms including disease shrinkage and disease stabilization for >4 months. Many women have stayed on for >a year! #gyncsm |
| Christine (Cissy) White @healWRITEnow @ShannonWestin I was glad to see this research because it seems that this is a drug that gets pushed hard even though the side effects can be brutal. #gyncsm |
| Nita Lee @NitaKarnikLee T3: #gyncsm: very important study! that was negative but we can learn to avoid over treatment with worse toxicity w/o benefit https://t.co/RwNaUGvRcH |
| Dee Sparacio @womenofteal @btrfly12 Big name - Pafolacianine Sodium injection (OTL38) agent lit up tumors with an overexpression of folate receptor alpha so surgeon could remove. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: T4: T4: What are some of the "hot topics" in gynecologic cancer research currently (PARPs, cytoreductive surgery, immunotherapy, other)? What is still up for debate that patients/survivors/advocates should be aware of? #gyncsm |
| Dee Sparacio @womenofteal RT @ShannonWestin: We evaluated the wee1 inhibitor adavosertib alone or in combination with olaparib in women w #PARPi resistant #OvarianCancer - we saw activity in both arms including disease shrinkage and disease stabilization for >4 months. Many women have stayed on for >a year! #gyncsm |
| Nita Lee @NitaKarnikLee RT @womenofteal: T1 a great overview @ocrahope of #SGOmtg from advocates @Stigetta and @KathleenMaxian https://t.co/cdQIVm5yRv #gyncsm |
| Dee Sparacio @womenofteal RT @NitaKarnikLee: T3: #gyncsm: T3: #gyncsm: very important study! that was negative but we can learn to avoid over treatment with worse toxicity w/o benefit https://t.co/RwNaUGvRcH |
| Suzie Siegel @SuzieSiegel This study by @Carisls was important at #ASCO21 for differentiating uterine #leiomyosarcoma from LMS elsewhere in the body. #gyncsm |
| Christina Lizaso @btrfly12 #gyncsm @ocrahope also provided post-meeting highlights from AACR (American Association for Cancer Research): https://t.co/p5ibmWIvfp |
| Christina Lizaso @btrfly12 RT @SuzieSiegel: This study by @Carisls was important at #ASCO21 for differentiating uterine #leiomyosarcoma from LMS elsewhere in the body. #gyncsm |
| Nita Lee @NitaKarnikLee RT @btrfly12: T1: T1: Here's a link to the #SGOMtg recap of media coverage following their conference. Good place to start and figure out what you might want to dig deeper into. #gyncsm https://t.co/y2SlEgnl9x |
| Christina Lizaso @btrfly12 RT @NitaKarnikLee: T3: #gyncsm: T3: #gyncsm: very important study! that was negative but we can learn to avoid over treatment with worse toxicity w/o benefit https://t.co/RwNaUGvRcH |
| Patsy Hinson @patsyhinson T4 I’m wanting more patients eligible for trials. We, as advocates, need to question this, particularly when we are on trial teams. #gyncsm |
| Christina Lizaso @btrfly12 RT @patsyhinson: T4 I’m wanting more patients eligible for trials. We, as advocates, need to question this, particularly when we are on trial teams. #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @patsyhinson: T4 I’m wanting more patients eligible for trials. We, as advocates, need to question this, particularly when we are on trial teams. #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @NitaKarnikLee: T3: #gyncsm: T3: #gyncsm: very important study! that was negative but we can learn to avoid over treatment with worse toxicity w/o benefit https://t.co/RwNaUGvRcH |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @btrfly12: T1: T1: Here's a link to the #SGOMtg recap of media coverage following their conference. Good place to start and figure out what you might want to dig deeper into. #gyncsm https://t.co/y2SlEgnl9x |
| Sarah Temkin @temkins A3: There were so many negative trials this year! But knowing that interventions cause harm without benefit (adding chemo in cx cancer, immunotherapy to ov cancer) is incredibly important to guide future therapies. #gyncsm |
| Dee Sparacio @womenofteal T3 I was excited about a novel GEM vaccine every 4 weeks as maintenance, 91 patients Gem well tolerated. Benefit for Homologous Recombination proficient patients #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @patsyhinson: T2 hard to hear about Negative trials. We learn what not to do; however, it’s disheartening for those in treatment. #gyncsm |
| Christine (Cissy) White @healWRITEnow @womenofteal @btrfly12 This sounds quite promising. I need to learn more. Was it discussed in surgery at early diagnosis as well as in recurrence? This is one of the many topics on the list I hope to talk with my oncologist about. #gyncsm |
| Christina Lizaso @btrfly12 RT @temkins: A3: A3: There were so many negative trials this year! But knowing that interventions cause harm without benefit (adding chemo in cx cancer, immunotherapy to ov cancer) is incredibly important to guide future therapies. #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @SuzieSiegel: This study by @Carisls was important at #ASCO21 for differentiating uterine #leiomyosarcoma from LMS elsewhere in the body. #gyncsm |
| Dee Sparacio @womenofteal @SuzieSiegel @carisls I was getting ready to share that info Suzie #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @btrfly12: T3: T3: From #ASCO21 I saw diversity and patient voice being highlighted in what seemed to be genuine ways. Long way to go but nice to see. The study about helping "light up" tumor so it can be removed looked fascinating. #gyncsm |
| Dee Sparacio @womenofteal RT @temkins: A3: A3: There were so many negative trials this year! But knowing that interventions cause harm without benefit (adding chemo in cx cancer, immunotherapy to ov cancer) is incredibly important to guide future therapies. #gyncsm |
| Sarah Temkin @temkins Different patients feel differently about scans, tumor markers, surveillance (some patients even like getting pelvic examinations!). What's most important is that communication is good so that you can land on a plan that works for patient and healthcare team. #gyncsm |
| Christine (Cissy) White @healWRITEnow @btrfly12 @ocrahope Super helpful @btrfly12 #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm T5: Any recent studies surrounding palliative care, survivorship, and psychosocial research that could help gyn cancer survivors? #gyncsm |
| Sarah Temkin @temkins RT @patsyhinson: T4 I’m wanting more patients eligible for trials. We, as advocates, need to question this, particularly when we are on trial teams. #gyncsm |
| Dee Sparacio @womenofteal RT @temkins: Different patients feel differently about scans, tumor markers, surveillance (some patients even like getting pelvic examinations!). What's most important is that communication is good so that you can land on a plan that works for patient and healthcare team. #gyncsm |
| Suzie Siegel @SuzieSiegel At #ASCO21, there was continued discussion on PARP inhibitors for (some) women with uterine #leiomyosarcoma. Also, the addition of temozolomide seemed promising. #gyncsm |
| Christina Lizaso @btrfly12 @Michele_w_1_L #gyncsm i mean, i want anxiety factored in, but I feel like potential anxiety in female patients maybe gets too much weight sometimes? and for me knowledge helps lesson anxiety |
| Dee Sparacio @womenofteal @healWRITEnow Here is the original tweet I wrote about the presentation #gyncsm |
| Sarah Temkin @temkins RT @ShannonWestin: We evaluated the wee1 inhibitor adavosertib alone or in combination with olaparib in women w #PARPi resistant #OvarianCancer - we saw activity in both arms including disease shrinkage and disease stabilization for >4 months. Many women have stayed on for >a year! #gyncsm |
| Dee Sparacio @womenofteal RT @SuzieSiegel: At #ASCO21, there was continued discussion on PARP inhibitors for (some) women with uterine #leiomyosarcoma. Also, the addition of temozolomide seemed promising. #gyncsm |
| Suzie Siegel @SuzieSiegel T5. I didn't see any specifically for women with gyn #sarcoma. In the #sarcoma world, #survivorship tends to focus on young people. #gyncsm |
| Sarah Temkin @temkins T3: For sure - this reinforces that chemotherapy holidays can be safe (and maybe even therapeutic). #gyncsm |
| Sarah Temkin @temkins RT @ShannonWestin: Very excited to get the final results for this combination in pts w clear cell #OvarianCancer I am hopeful that some of our translational analyses will help identify who benefits from #Immunotherapy #gyncsm |
| Dee Sparacio @womenofteal RT @temkins: T3: T3: For sure - this reinforces that chemotherapy holidays can be safe (and maybe even therapeutic). #gyncsm |
| Sarah Temkin @temkins RT @btrfly12: @Michele_w_1_L #gyncsm i mean, i want anxiety factored in, but I feel like potential anxiety in female patients maybe gets too much weight sometimes? and for me knowledge helps lesson anxiety |
 | Wafik S. El-Deiry, MD, PhD, FACP @weldeiry RT @drdonsdizon: A big question informed at #ASCO21: A big question informed at #ASCO21: Are uterine and soft tissue #leiomyosarcoma similar or different diseases? Presented by Dr. Tabitha Copeland for the @carisls #sarcoma POA. #gyncsm Answer: They are genomically DIFFERENT. Abstr #11555 https://t.co/NrjKDKaogR |
| Dee Sparacio @womenofteal From the plenary session #ASCO21 cervical Cancer study - OUTBACK showed that adjuvant chemotherapy added to standard chemoradiation therapy did not improve survival outcomes for women with locally advanced cervical cancer. #gyncsm |
| Christina Lizaso @btrfly12 I didn't see much on palliative care, survivorship, psychosocial for gyn patients - though I believe some came out earlier this year related to work by advocate @Stigetta Another good source for studies like that is the Oncology Nursing Society https://t.co/Ahof3mAZw9 #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm T6: Both #ASCO21 and #SGOmtg held sessions on disparities in gynecologic cancer care. What was highlighted and how can we work to decrease disparities? #gyncsm |
| Suzie Siegel @SuzieSiegel For the sake of women with gyn sarcoma, I wish we could get more cross-pollination between gyn oncologists and #sarcoma medical oncologists. They rarely attend each other's annual meetings. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: T6: T6: Both #ASCO21 and #SGOmtg held sessions on disparities in gynecologic cancer care. What was highlighted and how can we work to decrease disparities? #gyncsm |
| Nita Lee @NitaKarnikLee @btrfly12 @Michele_w_1_L Very good point #gyncsm such an important balance to address and acknowledge |
| Christina Lizaso @btrfly12 RT @SuzieSiegel: For the sake of women with gyn sarcoma, I wish we could get more cross-pollination between gyn oncologists and #sarcoma medical oncologists. They rarely attend each other's annual meetings. #gyncsm |
| IamCervivor @IamCervivor RT @womenofteal: From the plenary session #ASCO21 cervical Cancer study - OUTBACK showed that adjuvant chemotherapy added to standard chemoradiation therapy did not improve survival outcomes for women with locally advanced cervical cancer. #gyncsm |
| Dee Sparacio @womenofteal T5 There is this study by @DrAttai presented at ASCO. #gyncsm |
| Christina Lizaso @btrfly12 RT @womenofteal: T5 There is this study by @DrAttai presented at ASCO. #gyncsm |
| Sarah Temkin @temkins T6: The first step is admitting that there is a problem which is why I was so glad to see inequities highlighted. We can ask questions of our healthcare systems, and advocate for our healthcare boardrooms to look like the waiting room... #gyncsm |
| Christina Lizaso @btrfly12 RT @temkins: T6: T6: The first step is admitting that there is a problem which is why I was so glad to see inequities highlighted. We can ask questions of our healthcare systems, and advocate for our healthcare boardrooms to look like the waiting room... #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm T7: For our remaining time, please feel free to ask questions about or highlight other recent research you find of interest. What studies are on the horizon? What areas would you like to see more research? Trying to cover a lot on this chat - thanks for coming along :) #gyncsm |
| Suzie Siegel @SuzieSiegel T6. Black women are more likely to get uterine sarcomas, compared with other racial/ethnic groups. Sarcomas tend to be more aggressive than endometrial carcinoma. But advocates can't seem to get any help in outreach. #gyncsm |
| Dee Sparacio @womenofteal RT @SuzieSiegel: T6. Black women are more likely to get uterine sarcomas, compared with other racial/ethnic groups. Sarcomas tend to be more aggressive than endometrial carcinoma. But advocates can't seem to get any help in outreach. #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @temkins: T3: T3: For sure - this reinforces that chemotherapy holidays can be safe (and maybe even therapeutic). #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @temkins: T6: T6: The first step is admitting that there is a problem which is why I was so glad to see inequities highlighted. We can ask questions of our healthcare systems, and advocate for our healthcare boardrooms to look like the waiting room... #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @SuzieSiegel: T6. Black women are more likely to get uterine sarcomas, compared with other racial/ethnic groups. Sarcomas tend to be more aggressive than endometrial carcinoma. But advocates can't seem to get any help in outreach. #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @womenofteal: T5 There is this study by @DrAttai presented at ASCO. #gyncsm |
| Christina Lizaso @btrfly12 #gyncsm - here was an SGO study around neuropathy |
| Tobey @BRCAinfo @gyncsm T7: cancer treatment is very expensive. Are there any resources available for those who want to partake in a clinical trial out of state & cannot afford the “room & board” expense? #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @womenofteal: From the plenary session #ASCO21 cervical Cancer study - OUTBACK showed that adjuvant chemotherapy added to standard chemoradiation therapy did not improve survival outcomes for women with locally advanced cervical cancer. #gyncsm |
| Dee Sparacio @womenofteal RT @btrfly12: #gyncsm - here was an SGO study around neuropathy |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @womenofteal: @healWRITEnow Here is the original tweet I wrote about the presentation #gyncsm |
| Dee Sparacio @womenofteal RT @BRCAinfo: @gyncsm T7: @gyncsm T7: cancer treatment is very expensive. Are there any resources available for those who want to partake in a clinical trial out of state & cannot afford the “room & board” expense? #gyncsm |
| Christina Lizaso @btrfly12 #gyncsm - from last year but still a good one :) |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @temkins: Different patients feel differently about scans, tumor markers, surveillance (some patients even like getting pelvic examinations!). What's most important is that communication is good so that you can land on a plan that works for patient and healthcare team. #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @womenofteal: T3 I was excited about a novel GEM vaccine every 4 weeks as maintenance, 91 patients Gem well tolerated. Benefit for Homologous Recombination proficient patients #gyncsm |
| Christina Lizaso @btrfly12 @BRCAinfo @gyncsm That is a great question - Surely there is some support out there for non-covered clinical trial expenses ? #gyncsm |
| Dee Sparacio @womenofteal T6 this is one of many session on Disparities I listened to at ASCO. #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @btrfly12: #gyncsm - from last year but still a good one :) |
| Christina Lizaso @btrfly12 RT @womenofteal: T6 this is one of many session on Disparities I listened to at ASCO. #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @BRCAinfo: @gyncsm T7: @gyncsm T7: cancer treatment is very expensive. Are there any resources available for those who want to partake in a clinical trial out of state & cannot afford the “room & board” expense? #gyncsm |
| Tobey @BRCAinfo @gyncsm I’d appreciate any information! #gyncsm |
| Patsy Hinson @patsyhinson I’d like to see more Data related to helping patients access trials outside their cancer center. #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @btrfly12: #gyncsm - here was an SGO study around neuropathy |
| Suzie Siegel @SuzieSiegel #gyncsm People need to include #RareCancers in their discussions of #inequity. In gyn #sarcoma, we have less money for research, fewer experts, and less patient support. |
| GYN Cancer | #GYNCSM @gyncsm Thanks to all who joined and shared. Note there will be no #gyncsm chat in July. Save the date for our next chat Wed, Aug 11, 2021 at 8pmET (new time for 2021) when we’ll discuss “Cancer Myths”. |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @temkins: A3: A3: There were so many negative trials this year! But knowing that interventions cause harm without benefit (adding chemo in cx cancer, immunotherapy to ov cancer) is incredibly important to guide future therapies. #gyncsm |
| Tobey @BRCAinfo @patsyhinson Exactly #gyncsm |
| Christina Lizaso @btrfly12 RT @SuzieSiegel: #gyncsm People need to include #RareCancers in their discussions of #inequity. In gyn #sarcoma, we have less money for research, fewer experts, and less patient support. |
| Christina Lizaso @btrfly12 RT @patsyhinson: I’d like to see more Data related to helping patients access trials outside their cancer center. #gyncsm |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin RT @womenofteal: T1 a great overview @ocrahope of #SGOmtg from advocates @Stigetta and @KathleenMaxian https://t.co/cdQIVm5yRv #gyncsm |
| Sarah Temkin @temkins RT @patsyhinson: I’d like to see more Data related to helping patients access trials outside their cancer center. #gyncsm |
| Sarah Temkin @temkins RT @gyncsm: Thanks to all who joined and shared. Note there will be no #gyncsm chat in July. Save the date for our next chat Wed, Aug 11, 2021 at 8pmET (new time for 2021) when we’ll discuss “Cancer Myths”. |
| Dee Sparacio @womenofteal @btrfly12 @BRCAinfo @gyncsm I think when Industry protocols are reviewed in addtion to inclusion /exclusion there should be consideration for support for travel , meals etc. Some studies do include stipends. #gyncsm |
| Sarah Temkin @temkins RT @womenofteal: T6 this is one of many session on Disparities I listened to at ASCO. #gyncsm |
| Dee Sparacio @womenofteal RT @SuzieSiegel: #gyncsm People need to include #RareCancers in their discussions of #inequity. In gyn #sarcoma, we have less money for research, fewer experts, and less patient support. |
| Suzie Siegel @SuzieSiegel @womenofteal I wonder how we can conclude that biology plays no part -- at least in uterine #sarcoma -- when we have insufficient research. #gyncsm |
| Michele E. Collins @Michele_w_1_L t7: the research regarding early detection not improving survival is disheartening. I was under the impression that when it is caught early, you have a better chance of long term survival?! #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Thanks to all who joined and shared. Note there will be no #gyncsm chat in July. Save the date for our next chat Wed, Aug 11, 2021 at 8pmET (new time for 2021) when we’ll discuss “Cancer Myths”. |
| Sarah Temkin @temkins RT @btrfly12: #gyncsm - from last year but still a good one :) |
| Dee Sparacio @womenofteal @SuzieSiegel excellent point. #gyncsm |
| Dee Sparacio @womenofteal Grateful for our #gyncsm co-moderators! @btrfly12 @ShannonWestin @temkins @journeycancer @DrBeckerSchutte #gyncsm |
| Christina Lizaso @btrfly12 @BRCAinfo @gyncsm the Patient Advocate Foundation is kind of a clearing house for what aid is out there - not sure if anything for trial costs #gyncsm https://t.co/vcJnYN4jjk |
| Dee Sparacio @womenofteal Remember to check https://t.co/Df2f7Okp35 for a transcript of the chat and resources #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Just joining #gyncsm? Sorry if you missed us due to our changing the chat time. #gyncsm is now held at 8pmET | 7pmCT | 5pmPT. Look for the chat recap and resource links to be posted on our blog shortly https://t.co/oAfi7Me49e |
| Shannon Westin, MD, MPH, FASCO @ShannonWestin @womenofteal @btrfly12 @temkins @journeycancer @DrBeckerSchutte Thanks Dee!!! Great topic #gyncsm |
| Gary L. Thompson @garyleethompson When I get frustrated about the noise and anger on Twitter, I tune in to things like the #gyncsm tweet chat and am reminded of all the good people and the good this platform can do!! |
| GYN Cancer | #GYNCSM @gyncsm As always, remember to tweet things of interest with hashtag #gyncsm to keep the conversation going between chats. Wishing wellness and safety for all. |
| Dee Sparacio @womenofteal My goodness - it is 9pm already . The time really flew by. Thanks @btrfly12 for leading this #gyncsm 2021 research review and for the docs and patients who attended and shared their thoughts and info. |
| Dee Sparacio @womenofteal RT @gyncsm: Just joining #gyncsm? Sorry if you missed us due to our changing the chat time. #gyncsm is now held at 8pmET | 7pmCT | 5pmPT. Look for the chat recap and resource links to be posted on our blog shortly https://t.co/oAfi7Me49e |
| Dee Sparacio @womenofteal RT @garyleethompson: When I get frustrated about the noise and anger on Twitter, I tune in to things like the #gyncsm tweet chat and am reminded of all the good people and the good this platform can do!! |
| Christina Lizaso @btrfly12 RT @garyleethompson: When I get frustrated about the noise and anger on Twitter, I tune in to things like the #gyncsm tweet chat and am reminded of all the good people and the good this platform can do!! |
| Tobey @BRCAinfo @btrfly12 @gyncsm Thank you ~ I’ll take a look. I’ve been asked about resources from interested patients so many times & my reaction is 🤷♀️ #gyncsm |
| Tobey @BRCAinfo RT @btrfly12: @BRCAinfo @gyncsm the Patient Advocate Foundation is kind of a clearing house for what aid is out there - not sure if anything for trial costs #gyncsm https://t.co/vcJnYN4jjk |
 | NCI Cancer Stats @NCICancerStats The median age at diagnosis for #VulvarCancer is 69. Learn more about this cancer with our Cancer Stat Facts sheet: https://t.co/75ThX2FKfh #GynCSM https://t.co/fSliUHxVtG |
| Christina Lizaso @btrfly12 RT @womenofteal: @btrfly12 @BRCAinfo @gyncsm I think when Industry protocols are reviewed in addtion to inclusion /exclusion there should be consideration for support for travel , meals etc. Some studies do include stipends. #gyncsm |
| Dee Sparacio @womenofteal Here's a list of media articles written on research discussed at #SGOmtg https://t.co/TO1g913YvG #gyncsm |
| Christina Lizaso @btrfly12 @Michele_w_1_L need more ways to figure out who is at high risk vs general risk and new treatments :/ #gyncsm |
| Christina Lizaso @btrfly12 RT @NCICancerStats: The median age at diagnosis for #VulvarCancer is 69. Learn more about this cancer with our Cancer Stat Facts sheet: The median age at diagnosis for #VulvarCancer is 69. Learn more about this cancer with our Cancer Stat Facts sheet: https://t.co/75ThX2FKfh #GynCSM https://t.co/fSliUHxVtG |
#GynCSM content from Twitter.